These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 30761532)

  • 1. Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.
    de Kruijff IE; Sieuwerts AM; Onstenk W; Jager A; Hamberg P; de Jongh FE; Smid M; Kraan J; Timmermans MA; Martens JWM; Sleijfer S
    Int J Cancer; 2019 Aug; 145(4):1083-1089. PubMed ID: 30761532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients.
    Krawczyk N; Neubacher M; Meier-Stiegen F; Neubauer H; Niederacher D; Ruckhäberle E; Mohrmann S; Hoffmann J; Kaleta T; Banys-Paluchowski M; Reinecke P; Esposito I; Janni W; Fehm T
    BMC Cancer; 2019 Nov; 19(1):1101. PubMed ID: 31718606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
    Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
    PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
    Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
    Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
    Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
    Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Li W; O'Shaughnessy J; Hayes D; Campone M; Bondarenko I; Zbarskaya I; Brain E; Stenina M; Ivanova O; Graas MP; Neven P; Ricci D; Griffin T; Kheoh T; Yu M; Gormley M; Martin J; Schaffer M; Zelinsky K; De Porre P; Johnston SR
    Clin Cancer Res; 2016 Dec; 22(24):6002-6009. PubMed ID: 27267854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
    Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
    Clin Transl Oncol; 2015 Jul; 17(7):539-46. PubMed ID: 25613123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer.
    Stefanovic S; Deutsch TM; Riethdorf S; Fischer C; Hartkopf A; Sinn P; Feisst M; Pantel K; Golatta M; Brucker SY; Sütterlin M; Schneeweiss A; Wallwiener M
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal analysis of circulating tumor cell numbers improves tracking metastatic breast cancer progression.
    Szostakowska-Rodzos M; Fabisiewicz A; Wakula M; Tabor S; Szafron L; Jagiello-Gruszfeld A; Grzybowska EA
    Sci Rep; 2024 Jun; 14(1):12924. PubMed ID: 38839863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer.
    Onstenk W; Sieuwerts AM; Weekhout M; Mostert B; Reijm EA; van Deurzen CH; Bolt-de Vries JB; Peeters DJ; Hamberg P; Seynaeve C; Jager A; de Jongh FE; Smid M; Dirix LY; Kehrer DF; van Galen A; Ramirez-Moreno R; Kraan J; Van M; Gratama JW; Martens JW; Foekens JA; Sleijfer S
    Cancer Lett; 2015 Jun; 362(1):36-44. PubMed ID: 25797316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
    Galardi F; De Luca F; Biagioni C; Migliaccio I; Curigliano G; Minisini AM; Bonechi M; Moretti E; Risi E; McCartney A; Benelli M; Romagnoli D; Cappadona S; Gabellini S; Guarducci C; Conti V; Biganzoli L; Di Leo A; Malorni L
    Breast Cancer Res; 2021 Mar; 23(1):38. PubMed ID: 33761970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
    Mu Z; Benali-Furet N; Uzan G; Znaty A; Ye Z; Paolillo C; Wang C; Austin L; Rossi G; Fortina P; Yang H; Cristofanilli M
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of Estrogen Receptor Status from Primary Tumors to Metastasis and Serially Collected Circulating Tumor Cells.
    Forsare C; Bendahl PO; Moberg E; Levin Tykjær Jørgensen C; Jansson S; Larsson AM; Aaltonen K; Rydén L
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
    Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
    Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.